MAHAMOX-CV DUO

136.00

  Ask a Question
Category:

Description

💊 Composition

  • Amoxicillin – a broad-spectrum penicillin-type antibiotic that kills bacteria by stopping their cell wall formation.
  • Clavulanic Acid – a beta-lactamase inhibitor that prevents bacteria from destroying the amoxicillin, making the antibiotic more effective against resistant bacteria.

The exact strength varies by formulation (dry syrup, tablets, etc.), but common ones include:

  • Amoxicillin + Clavulanic acid dry syrup (e.g., 400 mg / 57 mg per 5 ml) for children.
  • Similar combination can also appear in tablet forms with adjusted strengths depending on brand and prescription.

🦠 What It’s Used For

Mahamox-CV Duo is prescribed for treating bacterial infections caused by susceptible organisms, including infections of the:

  • Respiratory tract (bronchitis, pneumonia)
  • Ear, nose, and throat
  • Urinary tract
  • Skin and soft tissues
  • Bones, joints, and dental (tooth) infections
    It does not work against viral infections like common colds or flu.

🧠 How It Works

  • Amoxicillin attacks and kills bacteria by disrupting their cell walls.
  • Clavulanic acid blocks bacterial enzymes (beta-lactamases) that normally break down amoxicillin, preventing resistance.

⚠️ Precautions

  • Prescription required – only take with doctor’s approval.
  • Complete the full course even if you feel better, to prevent recurrence or resistance.
  • Tell your doctor about allergies (especially to penicillins) and existing kidney/liver issues.
  • Take with food to reduce stomach upset.

🩺 Common Side Effects

Possible side effects may include:

  • Nausea, vomiting
  • Diarrhea
  • Abdominal discomfort
  • Mild allergic reactions (rash)
    These are usually mild — inform your doctor if symptoms persist or worsen.

Reviews

There are no reviews yet.

Be the first to review “MAHAMOX-CV DUO”

Your email address will not be published. Required fields are marked *

No more offers for this product!

General Inquiries

There are no inquiries yet.